The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis

BACKGROUND: In both first or subsequent therapy of patients with non-small cell lung cancer (NSCLC), some programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have shown prominent efficacy and safety. However, the disease spectra of side effects in different therapy time...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yilin, Pang, Peilin, Xie, Zihong, Wang, Nian, Liang, Hengrui, Zhao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797275/
https://www.ncbi.nlm.nih.gov/pubmed/35117689
http://dx.doi.org/10.21037/tcr.2020.03.82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797275/
https://www.ncbi.nlm.nih.gov/pubmed/35117689
http://dx.doi.org/10.21037/tcr.2020.03.82

Ejemplares similares